Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Asset Writedowns and Impairment (2018 - 2020)

Outlook Therapeutics (OTLK) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $104296.0 as the latest value for Q2 2020.

  • On a quarterly basis, Asset Writedowns and Impairment rose 104.8% to $104296.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $8.9 million, a N/A change, with the full-year FY2020 number at $527624.0, down 95.32% from a year prior.
  • Asset Writedowns and Impairment was $104296.0 for Q2 2020 at Outlook Therapeutics, down from $423328.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $8.3 million in Q3 2019 to a low of $50927.0 in Q2 2019.
  • A 3-year average of $2.0 million and a median of $492531.5 in 2019 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 104.8% in 2020; the steepest drop was 24.64% in 2020.
  • Outlook Therapeutics' Asset Writedowns and Impairment stood at $2.3 million in 2018, then soared by 253.62% to $8.3 million in 2019, then plummeted by 98.74% to $104296.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Asset Writedowns and Impairment are $104296.0 (Q2 2020), $423328.0 (Q1 2020), and $8.3 million (Q3 2019).